

c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and

d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

in an amount sufficient to ameliorate a symptom of the asthmatic disorder, such that the asthmatic disorder is treated.

54. (New) The method of claim 53, wherein the 8F4 inhibitory molecule is a monoclonal antibody that recognizes a human 8F4 polypeptide.

55. (New) The method of Claim 54, wherein the monoclonal antibody recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.

56. (New) The method of Claim 54, wherein the monoclonal antibody recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.

57. (New) The method of Claim 54, wherein the monoclonal antibody recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.

58. (New) The method of Claim 54, wherein the monoclonal antibody recognizes a human 8F4 polypeptide present on activated human CD4⁺ T lymphocytes and activated human CD8⁺ T lymphocytes.

59. (New) The method of claim 53, wherein the 8F4 inhibitory molecule is an 8F4 polypeptide.

REMARKS

The title has been amended to more specifically describe the elected subject matter. The specification has also been amended to correct the priority information of the